Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

STRO : 1.8800 (+3.30%)
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Progress on IND Applications and Clinical Trials

Sutro Biopharma reports significant advancements in ADC technology, ongoing trials, and robust financial resources.Quiver AI SummarySutro Biopharma, Inc. announced in its third-quarter 2024 financial results...

STRO : 1.8800 (+3.30%)
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

STRO : 1.8800 (+3.30%)
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

STRO : 1.8800 (+3.30%)
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

STRO : 1.8800 (+3.30%)
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

STRO : 1.8800 (+3.30%)
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

/CNW/ -- USA News Group – In the oncology world, there's been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However,...

ONCY : 0.8310 (-6.36%)
NVS : 97.11 (+0.35%)
LNTH : 89.29 (-2.89%)
STRO : 1.8800 (+3.30%)
ZYME : 14.14 (+4.12%)
ONC.TO : 1.19 (-9.16%)
Recent Breakthroughs in Cancer Research Could Impact These Key Companies

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – In the oncology world, there’s...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
NVS : 97.11 (+0.35%)
LNTH : 89.29 (-2.89%)
STRO : 1.8800 (+3.30%)
ZYME : 14.14 (+4.12%)
Why Investors Are Suddenly Excited About Vaxcyte

Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.

PCVX : 86.53 (+0.37%)
PFE : 26.36 (+2.29%)
MRNA : 39.39 (-0.43%)
STRO : 1.8800 (+3.30%)
MRK : 98.05 (-1.48%)
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones

- Collaboration with Astellas on discovery and development of iADCs for up to three targets, includes an upfront payment of $90 million and $422.5 million...

STRO : 1.8800 (+3.30%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar